The Start of the First-Ever ADNP Clinical Trial Marks Historic Moment in ADNP Research History!
|
Researchers at the Gozes Lab have identified a potential drug treatment for children with ADNP, called CP201/NAP. For the first time, we have in front of us a possible treatment for children with ADNP Syndrome. 2017 marks the initiation of the clinical trial of CP201/NAP for ADNP Syndrome.
RECRUITMENT FOR THIS TRIAL HAS NOT YET BEGUN
RECRUITMENT FOR THIS TRIAL HAS NOT YET BEGUN
Coronis NeuroSciences is a specialty pharma company focused on the development of Innovative therapies for Neurocognitive and Neurodegenerative disorders.
Coronis’ pipeline currently includes an innovative drug for major for ADNP Syndrome and is in the pre-clinical stage. CP201 is the Coronis' leading drug and is developed to treat ADNP-Related Syndrome.
Coronis’ pipeline currently includes an innovative drug for major for ADNP Syndrome and is in the pre-clinical stage. CP201 is the Coronis' leading drug and is developed to treat ADNP-Related Syndrome.